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A BST R AC T  
The global burden of chronic kidney disease (CKD) is rapidly increasing with a projection of 
becoming the 5th most common cause of years of life lost globally by 2040. Aggravatingly, CKD is 
a major cause of catastrophic health expenditure. The costs of dialysis and transplantation consume 
up to 3% of the annual healthcare budget in high-income countries. Crucially, however, the onset and 
progression of CKD is often preventable. In 2020, the World Kidney Day campaign highlights the 
importance of preventive interventions – be it primary, secondary or tertiary. This complementing 
article focuses on outlining and analyzing measures that can be implemented in every country to 
promote and advance CKD prevention. Primary prevention of kidney disease should focus on the 
modification of risk factors and addressing structural abnormalities of the kidney and urinary tracts, 
as well as exposure to environmental risk factors and nephrotoxins. In persons with pre-existing 
kidney disease, secondary prevention, including blood pressure optimization and glycemic control, 
should be the main goal of education and clinical interventions. In patients with advanced CKD, 
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management of co-morbidities such as uremia and cardiovascular disease is a highly recommended 
preventative intervention to avoid or delay dialysis or kidney transplantation. Political efforts are 
needed to proliferate the preventive approach. While national policies and strategies for non-
communicable diseases might be present in a country, specific policies directed toward education and 
awareness about CKD screening, management and treatment are often lacking. Hence, there is an 
urgent need to increase the awareness of the importance of preventive measures throughout 
populations, professionals and policy makers. 
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Introduction 
Around 850 million people currently are 
affected by different types of kidney disorders 
[1]. Up to one in ten adults worldwide has 
chronic kidney disease (CKD), which is 
invariably irreversible and mostly progressive. 
The global burden of CKD is increasing, and 
CKD is projected to become the 5th most 
common cause of years of life lost globally by 
2040 [2].  If CKD remains uncontrolled and if 
the affected person survives the ravages of 
cardiovascular and other complications of the 
disease, CKD progresses to end-stage renal 
disease (ESRD), where life cannot be sustained 
without dialysis therapy or kidney 
transplantation. Hence, CKD is a major cause 
of catastrophic health expenditure [3]. The 
costs of dialysis and transplantation consume  
 
 
2–3% of the annual health-care budget in high-
income countries; spent on less than 0.03% of 
the total population of these countries [4]. 
Importantly, however, kidney disease can be 
prevented and progression to ESRD can be 
delayed with appropriate access to basic 
diagnostics and early treatment including life 
style modifications and nutritional 
interventions [4-8]. Despite this, access to 
effective and sustainable kidney care remains 
highly inequitable across the world, and kidney 
disease a low health priority in many countries.  
Kidney disease is crucially missing from the 
international agenda for global health. Notably 
absent from the impact indicators for the 
Sustainable Development Goal (SDG) Goal 3. 
Target 3.4: By 2030 (By 2030, reduce by one 
third premature mortality from non-
communicable diseases (NCDs) through 
prevention and treatment and promote mental 
health and well-being) and the latest iteration 
of the Untied Nation (UN) Political 
Declaration on NCDs, kidney diseases 
urgently need to be given political attention, 
priority and consideration [9]. Current global 
political commitments on NCDs focus largely 
on four main diseases: cardiovascular disease 
(CVD), cancer, diabetes, and chronic 
respiratory diseases. Yet, it is estimated that 
55% of the global NCD burden is attributed to 
diseases outside of this group [10]. 
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Furthermore, kidney disease frequently co-
exists with the ‘big’ four NCDs, which leads to 
worse health outcomes. CKD is a major risk 
factor for heart disease and cardiac death, as 
well as for infections such as tuberculosis, and 
is a major complication of other preventable 
and treatable conditions including diabetes, 
hypertension, HIV and hepatitis [4-7]. As the 
Sustainable Development Goals (SDG) and 
Universal Health Coverage (UHC) agendas 
progress and provide a platform for raising 
awareness of NCD health care and monitoring 
needs, targeted action on kidney disease 
prevention should become integral to the 
global policy response [1]. The global kidney 
health community calls for the recognition of 
kidney disease and effective identification and 
management of its risk factors as a key 
contributor to the global NCD burden and the 
implementation of an integrated and people’s 
centered approach to care. 
 
Definition and Classification of CKD 
Prevention 
According to the expert definitions including 
the Center for Disease Control and Prevention 
[11], the term “prevention” refers to activities 
that are typically categorized by the following 
three definitions: (1) Primary Prevention, 
implies intervening before health effects occur 
in an effort to prevent the onset of illness or 
injury before the disease process begins (2) 
Secondary Prevention suggests preventive 
measures that lead to early diagnosis and 
prompt treatment of a disease to prevent more 
severe problems developing and includes 
screening to identify diseases in the earliest 
stages, and (3) Tertiary Prevention indicates 
managing disease after it is well established in 
order to control disease progression and the 
emergence of more severe complications, 
which is often by means of targeted measures 
such as pharmacotherapy, rehabilitation, and 
screening for and management of 
complications.  These definitions have 
important bearing in the prevention and 
management of the chronic kidney disease 
(CKD), and accurate identification of risk 
factors that cause CKD or lead to faster 
progression to renal failure as shown in Figure 
1 are relevant in health policy decisions and 
health education and awareness related to 
CKD [12]. 
 
Primary Prevention of CKD  
The incidence (new cases) and prevalence 
(cumulative pre-existing cases) of CKD have 
been rising worldwide [13]. This primary level 
of prevention requires awareness of modifiable 
CKD risk factors and efforts to focus 
healthcare resources on those patients who are 
at the highest risk of developing new onset or 
de novo CKD.   
Measures to achieve effective primary 
prevention should focus on the two leading risk 
factors for CKD including diabetes mellitus 
and hypertension. Evidence suggests that an 
initial mechanism of injury is renal 
hyperfiltration with seemingly elevated 
glomerular filtration rate, (GFR), above 
normal ranges. This is often the result of 
glomerular hypertension that is often seen in 
patients with obesity or diabetes mellitus, but 
it can also occur after a high dietary protein 
intake [8]. Other CKD risk factors include 
polycystic kidneys or other congenital or 
acquired structural anomalies of the kidney 
and urinary tracts, primary glomerulonephritis, 
exposure to nephrotoxic substances or 
medications (such as nonsteroidal anti-
inflammatory drugs), having one single 
kidney, e.g. solitary kidney after cancer 
nephrectomy, high dietary salt intake, 
inadequate  hydration  with  recurrent  volume  
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depletion, heat stress, exposure to pesticides 
and heavy metals (as has been speculated as the 
main cause of Mesoamerican Nephropathy), 
and possibly high protein intake in those at 
higher risk of CKD [8]. Among non-
modifiable risk factors are advancing age and 
genetic factors such as apolipoprotein 1 
(APOL1) gene that is mostly encountered in 
those with sub-Saharan African ethnicity, 
especially among African Americans.  Certain 
disease states may cause de novo CKD such as 
cardiovascular and atheroembolic diseases 
(also known as secondary cardiorenal 
syndrome) and liver diseases (hepatorenal 
syndrome). Table 1 shows some of the risk 
factors of CKD.  
Among measures to prevent emergence of de 
novo CKD are screening efforts to identify and 
manage persons at high risk of CKD, 
especially  those  with   diabetes  mellitus  and  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
hypertension. Hence, targeting primordial risk 
factors of these two conditions including 
metabolic syndrome and overnutrition is 
relevant to primary CKD prevention as is 
correcting obesity [14]. Promoting healthier 
lifestyle is an important means to that end 
including physical activity and healthier diet. 
The latter should be based on more plant-based 
foods with less meat, less sodium intake, more 
complex carbohydrates with higher fiber 
intake, and less saturated fat. In those with 
hypertension and diabetes, optimizing blood 
pressure and glycemic control has shown to be 
effective in preventing diabetic and 
hypertensive nephropathies. A recent expert 
panel suggested that persons with solitary 
kidney should avoid high protein intake above 
1 gram per kilogram body weight per day [15]. 
Obesity should be avoided, and weight 
reduction strategies should be considered [14]. 
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Secondary Prevention in CKD  
Evidence suggests that among those with 
CKD, the vast majority have early-stage of the 
disease. i.e., CKD Stages 1 and 2 with 
microalbuminuria (30 to 300 mg/day) or CKD 
Stage 3B (eGFR between 45 to 60 
ml/min/1.73m2) [16].  In these persons with 
preexisting disease, the “secondary 
prevention” of CKD has the highest priority. 
For these earlier stages of CKD, the main goal 
of kidney health education and clinical 
interventions is how to slow disease 
progression. Uncontrolled or poorly controlled 
hypertension is one of the most established risk 
factors for faster CKD progression. The 
underlying pathophysiology of faster CKD 
progression relates to ongoing damage to the 
kidney structure and loss of nephrons with 
worsening interstitial fibrosis as it happens 
with sustained hypertension.  
The cornerstone of the pharmacotherapy in 
secondary prevention is the use of angiotensin 
pathway modulators, also known as renin-
angiotensin-aldosterone system inhibitors 
(RAASi). These drugs reduce both systemic 
blood pressure and intraglomerular pressure by 
opening efferent arterioles of the glomeruli, 
hence, leading to longevity of the remaining 
nephrons.  Low protein diet appears to have a 
synergistic effect on RAASi therapy [17]. In 
terms of the potential effect of controlling 
glycemic status and correcting obesity on the 
rate of CKD progression, there are mixed data. 
However, recent data suggest that a new class 
of anti-diabetic medications known as sodium-
glucose cotransporter-2 Inhibitors (SGLT2i) 
can slow CKD progression, but this effect may 
not be related to glycemic modulation of the 
medication. Whereas acute kidney injury 
(AKI) may or may not cause de novo CKD, 
AKI events that are superimposed on 
preexisting CKD may accelerate disease 
progression [18]. A relatively recent case of 
successful secondary prevention that 
highlights the significance of implementing 
preventive strategies in CKD is the use of a 
vasopressin V (2)-receptor antagonists in 
Adult Polycystic Kidney Disease (ADPKD) 
[19]. 
 
Tertiary Prevention in CKD  
In patients with advanced CKD, management 
of uremia and related comorbid conditions 
such as anemia, mineral and bone disorders, 
and cardiovascular disease is of high priority, 
so that these patients can continue to achieve 
highest longevity. These measures can be 
collectively referred to as “tertiary prevention” 
of CKD. In these individuals, cardiovascular 
disease burden is exceptionally high, 
especially if they have underlying diabetes or 
hypertension, while they often do not follow 
other traditional profile of cardiovascular risk 
such as obesity or hyperlipidemia. Indeed, in 
these patients, a so-called “reverse 
epidemiology” exist, in that hyperlipidemia 
and obesity appear to be protective at this 
advanced stage of CKD. This could be due to 
the overshadowing impact of the “protein-
energy wasting” (PEW) that happens more 
frequently with worsening uremia and which is 
associated with weight loss and poor outcomes 
including cardiovascular disease and death. 
Whereas many of these patients, if they survive 
ravages of PEW and cardiovascular disease, 
will eventually receive renal replacement 
therapy in form of dialysis therapy or kidney 
transplantation, a new trend is emerging to 
maintain them longer without dialysis by 
implementing conservative management of 
CKD. However, in some with additional 
comorbidities such as metastatic cancers, 
palliative measures with supportive care can be 
considered.  
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Approaches to identification of Chronic 
Kidney Diseases 
The lack of awareness of CKD around the 
world is one of the reasons for late presentation 
of CKD in both developed and developing 
economies [20-22]. The overall CKD 
awareness among general population and even 
high cardiovascular risk groups across 12 low-
income and middle-income countries was less 
than 10% [22].  
Given its asymptomatic nature, screening of 
CKD plays an important role in early 
detection. Consensus and Positional 
Statements have been published by 
International Society of Nephrology [23], 
National kidney Foundation [24], Kidney 
Disease Improving Global Outcomes [25], 
NICE Guidelines [26] and Asian Forum for 
CKD Initiatives [27]. There was lack of trials 
to evaluate screening and monitoring of CKD 
[28]. Currently most will promote a targeted 
screening approach to early detection of CKD. 
Some of the major groups at risk for targeted 
screening includes: Patients with diabetes, 
hypertension, those with family history of 
chronic kidney disease (CKD), individuals 
receiving potentially nephrotoxic drugs, herbs 
or substances or taking indigenous medicine, 
patients with past history of acute kidney 
injury and individuals older than 65 years 
[27,29]. CKD can be detected with 2 simple 
tests: a urine test for the detection of 
proteinuria and a blood test to estimate the 
glomerular filtration rate (GFR) [24,27].  
Given that currently a population screening for 
CKD is not recommended and it was claimed 
that it might add unintended harm to the 
general population being screened [28], there 
is no specialty society or preventive services 
group which recommends general screening 
[30]. Low-income to middle-income countries 
are ill-equipped to deal with the devastating 
consequences of CKD, particularly the late 
stages of the disease. There are suggestions 
that screening should primarily include high-
risk individuals, but also extend to those with 
suboptimal levels of risk, e.g., prediabetes and 
prehypertension [31].  
 
Cost-effectiveness of early detection 
programs 
Universal screening of the general population 
would be time-consuming, expensive and has 
been shown to be not cost-effective. Unless 
selectively directed towards high- risk groups, 
such as the case of CKDu in disadvantaged 
populations [32], according to a cost-
effectiveness analysis using a Markov decision 
analytic model, population-based dipstick 
screening for proteinuria has an unfavorable 
cost effectiveness ratio [33]. A more recent 
Korean study confirmed that their National 
Health Screening Program (NHSP) for chronic 
kidney disease (CKD) is more cost-effective 
for patients with diabetes or hypertension than 
the general population [34]. From an economic 
perspective, screening CKD by detection of 
proteinuria was shown to be cost-effective in 
patients with hypertension or diabetes in a 
systematic review [35].  The incidence 
of CKD, rate of progression, 
and effectiveness of drug therapy were major 
drivers of cost-effectiveness and thus 
CKD screening may be more cost-effective in 
populations with higher incidences of CKD, 
rapid rates of progression, and more effective 
drug therapy. 
    
A Rational Approach to CKD Early 
Detection 
The approach towards CKD early detection 
will include the decision for frequency of 
screening, who should perform the screening 
and intervention after screening [21].  
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Screening frequency for targeted individuals 
should be yearly if no abnormality is detected 
on initial evaluation. This is in line with the 
Kidney Disease Improving Global Outcomes 
(KDIGO) resolution that the frequency of 
testing should be according to the target group 
to be tested and generally needs not be more 
frequent than once per year [25]. Who should 
perform the screening is always a question 
especially when the healthcare professional 
availability is a challenge in lower income 
economies. Physicians, nurses, paramedical 
staff and other trained healthcare professionals 
are eligible to do the screening tests. 
Intervention after screening is also important 
and patients detected to have CKD should be 
referred to primary care and general physicians 
with experience in management of kidney 
disease for follow up. A management protocol 
should be provided to the primary care and 
general physicians. Further referral to 
nephrologists for management will be based on 
the well-defined protocols [22,25,27].  
 
Integration of CKD prevention into 
national NCD programs 
Given the close links between CKD and other 
NCDs, it is critical that CKD advocacy efforts 
be aligned with existing initiatives concerning 
diabetes, hypertension, and cardiovascular 
disease, particularly in LMIC. Some countries 
and regions have successfully introduced CKD 
prevention strategies as part of their NCD 
programs. As an example, in 2003, a kidney 
health promotion program was introduced in 
Taiwan, with its key components including a 
ban on herbs containing aristolochic acid, 
public-awareness campaigns, patient 
education, funding for CKD research, and the 
setting up of teams to provide integrated care 
[36]. In Cuba, the Ministry of Public Health 
has implemented a national program for the 
prevention of CKD. Since 1996 the program 
has followed several steps: 1) the analysis of 
the resources and health situation in the 
country; 2) epidemiological research to define 
the burden of CKD; and 3); a continuing 
education for nephrologists, family doctors, 
and other health professionals. The main goal 
has been to bring nephrology care closer to the 
community through a regional redistribution of 
nephrology services and joint management of 
CKD patients by primary healthcare 
physicians and nephrologists [37]. The 
integration of CKD prevention into NCDs 
program, has resulted in the reduction of renal 
and cardiovascular risks in the general 
population. Main outcomes have been the 
reduction in the prevalence of risk factors, such 
as low birth weight, smoking, and infectious 
diseases. There has been an increased rate of 
the diagnosis of diabetes and of glycemic 
control, as well as an increased diagnosis of 
patients with hypertension, higher prescription 
use of renoprotective treatment with ACEI and 
higher rates of blood pressure control [38]. 
Recently, the US Department of Health and 
Human Services has introduced an ambitious 
program to reduce the number of Americans 
developing end-stage renal disease by 25 
percent by 2030. The program, known as the 
Advancing American Kidney Health Initiative, 
has set goals with metrics to measure its 
success; among them is to put more efforts to 
prevent, detect, and slow the progression of 
kidney disease, in part by addressing 
traditional risk factors like diabetes and 
hypertension. To reduce the risk of kidney 
failure, the program contemplates advancing 
public health surveillance and research to 
identify populations at risk and those in early 
stages of kidney disease, and to encourage 
adoption of evidence-based interventions to 
delay or stop progression to kidney failure 
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[39]. Ongoing programs, like the Special 
Diabetes Program for Indians (SDPI) 
represents an important part of this approach 
by providing team-based care and care 
management. Since its implementation, the 
incidence of diabetes-related kidney failure 
among American Native populations 
decreased by over 40 percent between 2000 
and 2015 [40].   
 
Involvement of Primary Care Physicians 
and Other Health Professionals 
Detection and prevention of CKD programs 
require considerable resources both in terms of 
manpower and funds. Availability of such 
resources will depend primarily on the 
leadership of nephrologists [41]. However, the 
number of nephrologists is not sufficient to 
provide renal care to the growing number of 
CKD patients worldwide. It has been 
suggested that most cases of non-progressive 
chronic kidney disease can be managed 
without referral to a nephrologist, and 
specialist referral can be reserved for patients 
with an estimated glomerular filtration rate < 
30 mL min per 1.73 per m2, rapidly declining 
kidney function, persistent proteinuria, or 
uncontrolled hypertension or diabetes [42]. It 
has been demonstrated that with an educational 
intervention the clinical competence of family 
physicians increases, resulting in preserved 
renal function in diabetic patients with early 
renal disease [43]. The practitioners who 
received the educational intervention used 
significantly more angiotensin-converting 
enzyme inhibitors, angiotensin-receptor 
blockers, and statins than did practitioners who 
did not receive it. The results were similar to 
those found in patients treated by nephrologists 
[44]. The role of primary health care 
professionals in the implementation of CKD 
prevention strategies in LMIC countries has 
been recently illustrated [45].  
The e-Learning has become an increasingly 
popular approach to medical education. Online 
learning programs for NCD prevention and 
treatment, including CKD, have been 
successfully implemented in Mexico. By 2015, 
over 5000 health professionals (including non-
nephrologists) had been trained using an 
electronic health education platform [46].  
 
Shortage of Nephrology Manpower – 
Implication on prevention 
The resources for nephrology care remain at 
critical levels in many parts of the world.  
Even in Western developed countries, 
nephrologists are frequently in short supply. In 
a selection of European countries with similar, 
predominantly public, health care systems, 
there was a substantial variation in the 
nephrology workforce. Countries like Italy, 
Greece, and Spain reported the highest ratios, 
while countries like Ireland, Turkey and the 
UK had the lowest ones [47]. In the USA, the 
number of nephrologists per 1000 ESRD 
patients has declined over the years, from 18 in 
1997 to 14 in 2010 [48]. The situation in the 
developing world is even worse. With the 
exception of Nigeria, Sudan, Kenya and South 
Africa, in many countries of sub-Saharan 
Africa there are fewer than 10 nephrologists. 
The number of nephrology nurses and dialysis 
technicians is also insufficient [49]. In Latin 
America the average number of nephrologists 
is 13.4 pmp. However, there is unequal 
distribution between countries; those with <10 
nephrologists pmp (Honduras, 2.1 pmp; 
Guatemala, 3.3 pmp; and Nicaragua, 4.6 pmp), 
and those exceeding 25 pmp (Cuba, 45.2 pmp; 
Uruguay, 44.2 pmp; and Argentina, 26.8 pmp) 
[50].  
The causes of this shortage are multiple. 
Potential contributors to this variation include 
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the increasing burden of CKD, erosion of 
nephrology practice scope by other specialists, 
lack of workforce planning in some countries 
relative to others, and the development of new 
care delivery models [48]. A novel strategy has 
been the successful ISN’s Fellowship program. 
Since its implementation in 1985, over 600 
fellows from > 83 LMIC have been trained. A 
significant number of fellowships were 
undertaken in selected developed centers 
within the fellow's own region. In a recent 
survey, 85% of responding fellows were re-
employed by their home institutions. [51,52].  
 
The Interdisciplinary Prevention Approach 
Since 1994, a National Institute of Health 
consensus advocated for early medical 
intervention in predialysis patients. Owing to 
the complexity of care of CKD, it was 
recommended that patients should be referred 
to a multidisciplinary team consisting of 
nephrologist, dietitian, nurse, social worker, 
and health psychologist, with the aim to reduce 
predialysis and dialysis morbidity and 
mortality [53]. In Mexico, a nurse-led, protocol 
driven, multidisciplinary program reported 
better preservation in eGFR and a trend in the 
improvement of quality of care of CKD 
patients similar to those reported by other 
Multidisciplinary Clinic (MDC) programs in 
the developed world. Additionally, more 
patients started dialysis non-emergently, and 
some obtained a pre-emptive kidney 
transplant. For those unable to obtain dialysis 
or who choose not to, a palliative care program 
is now being implemented [54]. Care models 
supporting primary care providers or allied 
health workers achieved better effectiveness in 
slowing kidney function decline when 
compared to those providing specialty care. 
Future models should address region-specific 
causes of CKD, increase the quality of 
diagnostic capabilities, establish referral 
pathways, and provide better assessments of 
clinical effectiveness and cost-effectiveness 
[55]  
 
Online educational programs for CKD 
prevention and treatment 
Whereas it is important to enhance the 
promotion and implementation of 
“Prevention” of kidney disease and kidney 
failure amongst healthcare professionals, it is 
equally important to promote “Prevention” 
with education programs for those at risk of 
kidney disease and kidney failure, and with the 
general population at large. It is a stepwise 
process, from awareness, engagement, 
participation, and empowerment and to 
partnership. As highlighted above, in general, 
the health literacy of the general population is 
low. Awareness and understanding of kidney 
disease are inadequate. Education is key to 
engaging patients with kidney disease. It is the 
path to self-management and patient-centered 
care. Narva found patient education is 
associated with better patient outcomes [56]. 
Obstacles include the complex nature of 
kidney disease information, low baseline 
awareness, limited health literacy and 
numeracy, limited availability of CKD 
information, and lack of readiness to learn. 
New education approaches should be 
developed through research and quality 
improvement efforts. Schatell found Web-
based kidney education is helpful in supporting 
patient self-management [57]. The Internet 
offers a wealth of resources on education. 
Understanding the types of Internet sources 
that CKD patients use today can help renal 
professionals to point patients in the right 
direction. It is important that reputable 
healthcare organizations, preferably at a 
national level, facilitate users to have easier 
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access to health information on their websites 
(Appendix 1).    
 
Appendix 1. Selected websites with information 
on CKD patient education. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The mode of communication currently used by 
patients and the population at large is through 
the internet - websites, portals, and other social 
media, such as Facebook and Twitter. There 
are also free apps on popular mobile devices 
providing education on kidney disease. There 
is no shortage of information on the internet. 
The challenge is how to effectively “push” 
important healthcare information in a targeted 
manner, and to facilitate users seeking 
information in their efforts to “pull” relevant 
and reliable information from the internet. It is 
important the “pushing” of health information 
is targeted and specific, relevant for the 
condition (primary, secondary or tertiary 
prevention), and is offered at the right time to 
the right recipient. It is possible with the use of 
information technology and informatics to 
provide relevant and targeted information for 
patients at high risk, coupling the information 
based on diagnosis and drugs prescribed. 
Engagement of professional society resources 
and patient groups is a crucial step to promote 
community partnership and patient 
empowerment on prevention. Additional 
resources may be available from charitable and 
philanthropic organizations.   
 
RENEWED FOCUS ON PREVENTION 
AND AWARENESS RAISING AND 
EDUCATION 
Given the pressing urgency pertaining to the 
need for increasing education and awareness 
on the importance of the preventive measures, 
we suggest the following goals to redirect the 
focus on plans and actions:  
1. Empowerment through health literacy in 
order to develop and support national 
campaigns that bring public awareness to 
prevention of kidney disease.   
2. Population-based approaches to manage key 
known risks for kidney disease, such as blood 
pressure control and effective management of 
obesity and diabetes.  
3. Implementation of the World Health 
Organization (WHO) 'Best Buys' approach 
including screening of at-risk populations for 
CKD, universal access to essential diagnostics 
of early CKD, availability of affordable basic 
technologies and essential medicines and task 
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shifting from doctors to front-line healthcare 
workers to more effectively target progression 
of CKD and other secondary preventative 
approaches. 
To that end, the motto ‘Kidney Health for 
Everyone, Everywhere’ is more than a tagline 
or wishful thinking. It is a policy imperative 
which can be successfully achieved if policy 
makers, nephrologists and healthcare 
professionals place prevention and primary 
care for kidney disease within the context of 
their Universal Health Coverage programs.  
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